Insulet Corporation
PODDInsulet Corporation (PODD) develops advanced insulin management systems, most notably its Omnipod insulin management system. The company focuses on innovative healthcare solutions for people with insulin-dependent diabetes, offering tubeless, wearable devices that provide continuous insulin delivery and improve quality of life. Founded in 2000, Insulet is headquartered in Massachusetts and is known for its commitment to enhancing diabetes care through user-friendly and technology-driven products.
Company News
Rosen Law Firm is encouraging investors who purchased securities of Insulet Corporation (PODD) between February 21, 2025 and May 26, 2026 to join a class action lawsuit. The lawsuit alleges that Insulet made false and misleading statements regarding defective manufacturing controls and procedures that created a foreseeable risk of product safety ...
Insulet Corporation (PODD) faces a class action securities fraud lawsuit alleging the company failed to disclose defective manufacturing controls that led to two voluntary medical device corrections of its Omnipod insulin delivery systems between March and May 2026. The disclosures triggered significant stock price declines of 6.9% and 5.1% respe...
A class action lawsuit has been filed against Insulet Corporation alleging that the company made materially false and misleading statements regarding its business operations and compliance policies. The complaint specifically claims that Insulet's manufacturing controls were defective, creating a foreseeable risk that products could violate safet...
Pomerantz LLP has filed a class action lawsuit against Insulet Corporation for alleged securities fraud. The complaint alleges that Insulet made false statements about its manufacturing controls and failed to disclose defective procedures that created safety risks. Two voluntary medical device corrections were announced in March and May 2026, res...
Rosen Law Firm is reminding investors who purchased Insulet Corporation securities between February 21, 2025 and May 26, 2026 of the August 31, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Insulet made false statements regarding defective manufacturing controls and procedures that created safety ris...
